Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma

Blood

Volumn 115, Issue 14, 2010, Pages 2763-2768

  Lambert, Jonathan R ^a   Bomanji, Jamshed B ^b   Peggs, Karl S ^a   Thomson, Kirsty J ^c   Chakraverty, Ronjon K ^a   Fielding, Adele K ^a   Kottaridis, Panagiotis D ^a   Roughton, Michael ^d   Morris, Emma C ^a,e   Goldstone, Anthony H ^c   Linch, David C ^a   Ell, Peter J ^b   Mackinnon, Stephen ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CARMUSTINE; CONTRAST MEDIUM; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SURVEILLANCE; DONOR; FEMALE; FOLLICULAR LYMPHOMA; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTE TRANSFUSION; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; RELAPSE; SURVIVAL RATE;

EID: 77951008602     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-255182     Document Type: Article

References (20)

1. de Lima M, van Besien KW, Giralt SA, et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997;19(2):121-127. (Pubitemid 27068247)
2. Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98(13):3595-3599.
3. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390-3400.
4. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365(9475):1934-1941.
5. Yuen AR, Kamel OW, Halpern J, Horning SJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol. 1995;13(7):1726-1733.
6. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100(13):4310-4316. (Pubitemid 35429668)
7. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004;104(13):3865-3871.
8. Vigouroux S, Michallet M, Porcher R, et al. Longterm outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica. 2007;92(5):627-634.
9. Peggs KS, Sureda A, QianW, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol. 2007;139(1):70-80.
10. Becherer A, Mitterbauer M, Jaeger U, et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia. 2002;16(2):260-267. (Pubitemid 34145144)
11. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood. 2003;102(1):53-59. (Pubitemid 36759635)
12. Svoboda J, Andreadis C, Elstrom R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2006;38(3):211-216.
13. Bloor AJ, Thomson K, Chowdhry N, et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(1):50-58. (Pubitemid 350286737)
14. Hart DP, Avivi I, Thomson KJ, et al. Use of 18FFDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions. Br J Haematol. 2005;128(6):824-829. (Pubitemid 40444876)
15. Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood. 2004;103(2):428-434.
16. Mackinnon S, Barnett L, Bourhis JH, et al. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood. 1992;80(12):3235-3241. (Pubitemid 23004529)
17. Visvikis D, Costa DC, Croasdale I, et al. CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET. Eur J Nucl Med Mol Imaging. 2003;30(3):344-353. (Pubitemid 36692858)
18. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-578.
19. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
20. Yoshimi A, Izutsu K, Takahashi M, et al. Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation. Am J Hematol. 2008;83(6):477-481. (Pubitemid 351742796)